Grenz Ray Therapy for Skin Disorders
This policy governs Aetna's coverage stance on the use of Grenz ray (ultrasoft x-ray) therapy for dermatologic conditions and applies to Aetna members and treating providers.
No material clinical or coverage changes in this revision.
Coverage Criteria
Experimental and Investigational
Covered when ALL of the following are met:
Policy statement - therapy not covered as medically necessary
Radiation therapy is contraindicated for benign cutaneous lesions, particularly for dermatoses of the head and neck, because published observations report radiation-induced skin tumors and other neoplasms following such exposures. The policy notes that although Grenz ray therapy has been proposed for benign dermatoses unresponsive to conventional treatments, this use remains controversial in the peer-reviewed literature and carries documented safety concerns.
Aetna considers Grenz ray therapy experimental and investigational for the treatment of dermatologic conditions due to inadequate evidence in the published peer‑reviewed medical literature regarding its effectiveness. As a result, Grenz ray therapy is not established as medically necessary for skin disorders and may be denied on that basis.
Coding
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.